NOTICES

NURSING RESEARCH EMPHASIS GRANTS FOR DOCTORAL PROGRAMS IN NURSING (NRE/DPN)—MORATORIUM ON RECEIPT OF APPLICATIONS
National Center for Nursing Research
Index: NURSING RESEARCH

NURSING STUDIES IN ESTABLISHED RESEARCH CENTERS AND CLINICAL TRIALS: NOTICE TO ALL NIH CENTER AND CLINICAL TRIALS DIRECTORS
National Center for Nursing Research
Index: NURSING RESEARCH

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

CLINICAL TRIALS OF ACTIVATED HUMAN LEUKOCYTES (RFP)
National Cancer Institute
Index: CANCER

THE DEVELOPMENT OF EVALUATION OF DRUGS FOR TREATMENT OF M. AVIUM-INTRACELLULARE INFECTIONS (RFP)
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

APPLICATION OF SHUTTLE VECTORS AND RELATED TECHNOLOGY TO STUDY THE MECHANISMS OF DNA DAMAGE, REPAIR, AND CELL SENSITIVITY TO IONIZING RADIATION. (RFA)
National Cancer Institute
Index: CANCER

PROGRAMS OF EXCELLENCE OF RESEARCH ON OSTEOPOROSIS (RFA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute on Aging
National Institute of Diabetes and Digestive and Kidney Diseases
Index: ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
AGING
DIABETES AND DIGESTIVE AND KIDNEY DISEASES

BASIC STUDIES OF DEVELOPMENTAL HEMOSTASIS (RFA)
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

EFFECTS OF DIET FAT AND FIBER ON LIPOPROTEIN METABOLISM (RFA)
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH ON THE ETIOLOGY OF DRUG ABUSE AMONG ETHNIC AND MINORITY JUVENILE POPULATIONS
National Institute on Drug Abuse
Office of Juvenile Justice and Delinquency Prevention, U S Department of Justice
Index: DRUG ABUSE

DRUG ABUSE SERVICES RESEARCH CONFERENCE GRANTS
National Institute on Drug Abuse
Index: DRUG ABUSE
NOTICES

NURSING RESEARCH EMPHASIS GRANTS FOR DOCTORAL PROGRAMS IN NURSING (NRE/DPN)--MORATORIUM ON RECEIPT OF APPLICATIONS

P.T. 34; K.W. 0785130

NATIONAL CENTER FOR NURSING RESEARCH

Sixteen institutions have received funding from the Division of Nursing, Bureau of Health Professions, Health Resources and Services Administration Nursing Research Emphasis program since its initiation in 1979. This program is now being examined to evaluate its impact on strengthening the research capabilities in schools of nursing with doctoral programs. Effective July 1, 1986, therefore, the National Center for Nursing Research is calling a moratorium on the receipt of new and competing NRE applications.

Faculty members in schools of nursing having doctoral programs should submit research grant applications under other mechanisms supported by the NCNR, the investigator initiated research project, program project, or FIRST award.

NURSING STUDIES IN ESTABLISHED RESEARCH CENTERS AND CLINICAL TRIALS: NOTICE TO ALL NIH CENTER AND CLINICAL TRIALS DIRECTORS

P.T. 34; K.W. 0755015, 0715035

NATIONAL CENTER FOR NURSING RESEARCH

The National Center for Nursing Research (NCNR) has been recently established at the NIH. The NCNR will support research grants and National Research Service Award (NRSA) training grants related to research on patient care, the promotion of health, the prevention of disease and mitigation of the effects of acute and chronic illnesses and disabilities. In support of studies of nursing interventions, procedures, delivery methods and ethics of patient care, NCNR programs are expected to complement other biomedical research programs that are primarily concerned with causes and treatment of disease.

The NCNR is particularly interested in making awards to nurse investigators working in well-established NIH supported centers and clinical trials where nursing research projects will complement ongoing activities. Requests for information should be addressed to:

Dr. Doris Bloch, NCNR
National Institutes of Health
Building 38A/B2E17
Bethesda, MD 20894
Telephone: (301) 496-0526

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

RFP AVAILABLE: N01-CM-67910-26

CLINICAL TRIALS OF ACTIVATED HUMAN LEUKOCYTES

P.T. 34, 44; K.W. 0745035, 0745055, 0730065, 0783010

NATIONAL CANCER INSTITUTE

The Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment (DCT), National Cancer Institute (NCI) is seeking organizations that will perform clinical trials using activated human leukocytes in cancer patients. The major objectives of this task shall be to:

1. Determine the antitumor activity of activating agents in combination with activated leukocytes in a variety of human cancers in patients with advanced disease and minimal prior therapy.

2. Define the toxicities of activating agents administered in combination with activated lymphocytes to patients with advanced cancer.
3 Evaluate new methods for activation of leukocytes and determine the optimum regimen and antitumor activity of activated leukocytes generated using the new methodology.

It is expected that awards will be made to 4-6 institutions to conduct studies for adult cancer patients and to one institution to conduct studies for pediatric patients. A four-year period of performance is expected for this project. In the duration of this contract, no fewer than 120 (40/year) evaluable patients will be studied at each institution. All patients must be treated at the Principal Investigator's own institution and directly under the Principal Investigator's care for initial evaluation, therapy and follow-up.

A minimum mandatory requirement has been established for this acquisition. The offeror must document the accrual of at least 40 evaluable adult patients to IRB-approved Phase II studies conducted at the offeror's institution from January 1, 1985, to December 31, 1985. Institutions applying for the pediatric portion of this contract must document the accrual of at least 25 evaluable patients to Phase II studies at the offeror's institution from January 1, 1985, to December 31, 1985. All patients must have been accrued at a single institution and this institution must be the same as that proposed for studies under this contract.

NCI expects to hold a preproposal conference with prospective offerors on September 3, 1986, for the purpose of providing information which may be helpful in the preparation of proposals and to answer any questions which offerors have regarding this solicitation. Complete instructions will be provided in the RFP package.

This synopsis is not a request for proposal. It is anticipated that RFP No. NCI-CH-67910-26 for the above described work will be available to interested offerors on or about August 11, 1986, with a due date for receipt of proposals on October 20, 1986.

Copies of the RFP may be obtained by sending a written request to:

Carolyn L. Swift, Contract Specialist
Treatment Contracts Section, Research Contracts Branch
National Cancer Institute
Blair Building, Room 228
Bethesda, Maryland 20892

RFP AVAILABLE: RFP-NIH-NIAID-AIDSP-87-11

THE DEVELOPMENT OF EVALUATION OF DRUGS FOR TREATMENT OF M. AVIUM-INTRACELLULARE INFECTIONS

P.T. 34; K.W. 0755025, 0715125, 0740005, 0710100

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

The Bacteriology and Virology Branch of the Microbiology and Infectious Diseases Program of the National Institute of Allergy and Infectious Diseases has a requirement for the development of additional drugs for the treatment of M. avium-intracellulare infections. The successful offeror must have the capabilities and facilities to evaluate potential anti-M. avium-intracellulare drugs, to utilize in vitro models for initial evaluation of the antimicrobials, to utilize in vivo models for final evaluation of active antimicrobials and to evaluate the results obtained from the in vivo models.

The NIAID sponsored project will take approximately five years to complete. This will be a cost reimbursement contract.

This is an announcement for an anticipated Request for Proposal (RFP). RFP-NIH-NIAID-AIDSP-87-11 will be issued on or about August 11, 1986, with a closing date tentatively set for October 1, 1986.

Requests for the RFP should be directed to the Chief, Contracts Management Branch, NIAID, NIH, Westwood Building, Room 707, Bethesda, Maryland 20892. Please provide this office with two (2) self-addressed mailing labels.

All responsible sources may submit a proposal which will be considered by NIAID.

This advertisement does not commit the Government to award a contract.
APPLICATION OF SHUTTLE VECTORS AND RELATED TECHNOLOGY TO STUDY THE MECHANISMS OF DNA DAMAGE, REPAIR, AND CELL SENSITIVITY TO IONIZING RADIATION.

P.T. 34; K.W. 0725015, 0755030, 0760080, 0765015, 1002019

NATIONAL CANCER INSTITUTE

Application Receipt Date: October 15, 1986

The Division of Cancer Etiology of the National Cancer Institute invites grant applications which utilize recent developments in recombinant DNA techniques to investigate the mechanisms of damage, repair and sensitivity of mammalian cells to ionizing radiation.

RESEARCH GOALS AND SCOPE

The goal of this RFA is to encourage research that will result in new techniques, approaches, and information which will advance our knowledge about the specific mechanisms of radiation-induced damage and repair, and the relationship of such processes to cell killing, developmental changes, and neoplastic transformation. Emphasis is placed on sensitive and specific quantitation of various DNA lesions (e.g., base substitutions, deletions, rearrangements, etc.) and the ability to carry out experiments on various cells in culture such as normal human fibroblasts, cells from patients with various radiation sensitive syndromes (including ultraviolet sensitivities), or mouse cells from inbred strains that are radiation sensitive or resistant.

Objectives would include but not be limited to the use of shuttle vectors and related technology as follows: (1) to determine the damage to shuttle vector marker genes when they are irradiated inside or outside of the cell and in the presence or absence of agents which alter their physicochemical response to radiation; (2) to measure the dependence of damage/repair processes on dose, dose protraction, and radiation quality, or to measure the combined effects of ionizing radiation with other agents such as promoters, other chemicals, or non-ionizing radiation; (3) to devise methods to distinguish between mutations arising at the point of DNA damage from mutations which arise in initially undamaged areas of DNA as a consequence of DNA damage elsewhere in the genome; (4) to investigate physiologic and genetic factors of host cells that influence mutagenesis or transformation such as host cells which have a genetic susceptibility or resistance to radiation, or cells which manifest cancer proneness.

MECHANISM OF SUPPORT

Awards will be made as traditional NIH research project grants. The maximum period for application is three years. It is anticipated that at least three individual research project grants will be awarded for the first year assuming the applications are of high scientific merit.

INQUIRIES

Copies of the complete RFA and additional information may be obtained from:

Raymond Gantt, Ph.D.
Low Level Radiation Effects Branch
Division of Cancer Etiology
National Cancer Institute
Landow Building, Room 8C-19
Bethesda, Maryland 20892
Tele. (301) 496-5266
BACKGROUND

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are inviting grant applications from interested institutions for Programs of Excellence of Research on Osteoporosis. Osteoporosis is a frequently occurring disease (or possibly several related diseases) that leads to weakened bone that fractures more easily than normal bone. The condition affects as many as 15-20 million individuals in the United States.

About 1.3 million fractures attributable to osteoporosis occur annually in people age 45 or older. Among those who live to be age 90, 32 percent of women and 17 percent of men will suffer a hip fracture, most due to osteoporosis combined with a fall. The vast majority of the approximately 200,000 hip fractures occurring each year are suffered by elderly people. The one year mortality of hip fracture victims probably exceeds 20 percent. The cost of all hip fractures exceeds $7 billion annually.

RESEARCH GOALS AND SCOPE

The goal of this RFA is to solicit coordinated multidisciplinary research in an area of special importance to the NIAMS, the NIA and the NIDDK. Areas of investigations of interest to the NIAMS, the NIA and the NIDDK include but are not limited to:

- Studies of the mechanisms underlying the regulation of resorption and formation of bone and how these mechanisms are disrupted and result in osteoporosis.
- Development of low cost, low risk, sensitive and specific methods for determining the quantity of bone in various anatomic structures, assessing the status of bone metabolism, and estimating the structural quality of various regions of the skeleton.
- Conducting epidemiologic investigations to further clarify risk factors including identification of previously unknown factors.
- Studies on the influence of preventive measures including establishment of greater bone mass in children and young adults and active prevention of bone loss in the postmenopausal period. Extensive clinical studies or trials of the current forms of estrogens or progestins will not be supported by this RFA.
- Investigations of treatments for individuals already afflicted with significant bone loss and/or fractures. Restoration of osteoporotic bone to bone of normal quality and strength is desired, including persons of very advanced age.

MECHANISM OF SUPPORT

The administrative and funding mechanism will be the Program Project Award. The regulations and the policies that govern the research grant programs of the Public Health Service will prevail. The award will support: (a) research projects, (b) core functions, and (c) feasibility studies. To be eligible for an award, an application must contain a minimum of three approved meritorious research projects.

The start date for funded projects will be approximately July 1, 1987. NIAMS, NIA and NIDDK anticipate funding a total of three program projects. The first year budget of each awarded program project must not exceed $500,000 direct cost. The total direct cost of each program project must not exceed $3,000,000.
METHOD OF APPLYING

Copies of the complete RFA, guidelines for structuring a program project application and methods of applying can be obtained from the program administrators:

Stephen L. Gordon, Ph.D. Evan C. Hadley, M.D.
NIAMS NIA
Westwood Building Building 31, Room 5C-21
Room 407 9000 Rockville Pike
Bethesda, Maryland 20892 Bethesda, Maryland 20892
301/496-7326 301/496-1033

Robert A. Tolman, Ph.D.
NIDDK
Westwood Building
Room 626
Bethesda, Maryland 20892
301/496-7504

RFA AVAILABLE: 86-HL-26-B

BASIC STUDIES OF DEVELOPMENTAL HEMOSTASIS

P.T. 34; K.W. 0705015, 0775000, 1002004, 1002008, 0785070, 0755030

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Application Receipt Date: November 17, 1986

The Blood Diseases Branch of the Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute (NHLBI) announces the availability of a Request for Applications (RFA) on the above subject. Copies of the RFA are currently available from staff of the NHLBI. Awards will be made to foreign institutions only for research of very unusual merit, need, and promise.

This program will support basic research on the development of the hemostatic system in the newborn to elucidate the molecular biology of the processes regulating hemostatic maturation in normal premature and term infants, and in infants with hemorrhagic and thrombotic diseases. It is anticipated that such research will establish causality between derangements in coagulation and fibrinolysis and the pathophysiology of these diseases as well as enhance understanding of the mechanisms underlying hemostatic disorders of the newborn.

Requests for copies of the RFA should be addressed to:

Diane L. Lucas, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building, Room 5A12
Bethesda, Maryland 20892
Telephone: (301) 496-5911
RFA AVAILABLE: 86-HL-27-H

EFFECTS OF DIET FAT AND FIBER ON LIPOPROTEIN METABOLISM

P.T. 34; K.W. 0765025, 0710095, 1003018, 0710070, 0785070

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Application Receipt Date: December 15, 1986

The Lipid Metabolism-Atherogenesis Branch of the Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute (NHLBI) announces the availability of a Request for Applications (RFA) on the above subject. Copies of the RFA are currently available from staff of the NHLBI.

This program will support clinical research in humans on the long-term effects (3 to 6 months) of dietary fat, fatty acid and fiber modification on lipoprotein structure, function and metabolism and will encourage simultaneous evaluation of these modifications on other atherogenesis parameters. It is expected that research will encompass a variety of approaches and involve expertise from several disciplines, including clinical nutrition, protein and lipid biochemistry, hematology and immunology.

Request for copies of the RFA should be addressed to:
Barbara H. Dennis, R.D., Ph.D.
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Federal Building, Room 401
7550 Wisconsin Avenue
Bethesda, Maryland 20892
Telephone: (301) 496-1681

ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH ON THE ETIOLOGY OF DRUG ABUSE AMONG ETHNIC AND MINORITY JUVENILE POPULATIONS

P.T. 34; K.W. 0404009, 0755030, 0403001, 0404000, 0411005, 0745055

NATIONAL INSTITUTE ON DRUG ABUSE AND OFFICE OF JUVENILE JUSTICE AND DELINQUENCY PREVENTION, U.S. DEPARTMENT OF JUSTICE

Application Receipt Dates: June 1, October 1, February 1

The National Institute on Drug Abuse (NIDA) and the Office of Juvenile Justice and Delinquency Prevention (OJJDP) have proposed to jointly fund a research program on the Etiology and Prevention of Drug Abuse Among Ethnic and Minority Juvenile Populations.

INTRODUCTION

Public concern over increased drug abuse among children and adolescents has stimulated a major effort on the part of researchers and clinicians to identify effective ways of intervening in this behavior. Although major strides have been taken in the area of etiology and preventive intervention research, these efforts have focused, in large part, on studies which examine drug abuse among white, middle class youth. Only limited information is available on the prevalence of drug abuse in ethnic and minority populations, as well as etiological and developmental factors that may play a role in determining vulnerability to drug abuse. In order to develop effective prevention and intervention strategies for ethnic and minority youth populations, etiologic research is essential for future program development at the Federal, State and local level.

The lack of such research is of particular concern since epidemiological survey data compiled through NIDA's DAWN and CODAP systems indicate that adult members of specific population subgroups (i.e., Blacks and Hispanics) are overrepresented in drug treatment programs and drug-related emergency hospital admissions, as well as in selected criminal justice actions. Furthermore, the data indicate an increasing trend in drug abuse among ethnic and minority populations.

Despite the recent leveling trend in the use of some psychoactive drugs among adolescents, drug and alcohol abuse by youth remains widespread. Further,
prevalence figures may represent underestimates of actual rates of use since they omit those likely to be heaviest users, (e.g., school dropouts and adolescents involved in the criminal justice system).

PURPOSE
The purpose of this research announcement is to encourage the scientific study of drug abuse among ethnic and minority juvenile populations from a variety of etiologic perspectives. This program is authorized under sections 301 and 515 of the Public Health Service Act (42 USC 241). Specific objectives of this research program include:

- identification of reciprocal effects between ethnic and minority group membership and special culturally-related factors which may influence initiating, maintaining, or relapsing into drug abuse; for example, studies are needed to evaluate the interactional effects of minority status, acculturation, and drug abuse.
- identification and analyses of factors related to access to drug, and risk of initiation, maintenance or relapse; for example, examination of drug availability and patterns of drug use among inner city minority youth.
- identification of developmental correlates and consequences of drug abuse behavior and the impact on society; for example, studies which examine behavioral and physiological risk factors which may play a role in the development of drug abuse and the effects of such use on ethnic and minority youth.
- development of conceptual models of the etiology and function of drug abuse; for example, studies could examine interrelationship of risk factors related to both criminal behavior and drug abuse.
- identification of naturally occurring support systems which promote the use or non-use of drugs; for example, studies of intergenerational traits associated with drug use.

ELIGIBILITY
Research grants are available to any public, nonprofit, or for-profit institution such as a university, college, hospital, or community agency, and units of State or local government, or authorized units of the Federal Government. NIDA encourages women and minorities to apply as principal investigators.

APPLICATION
The regular research grant application form PHS 398 (rev. 5/82) must be used in applying for these awards. However, State and local agencies should use form PHS 5161 (rev. 3/79). When applying, type in item 2 on page 1 of PHS 398, the name of this announcement, "Research on the Etiology of Drug Abuse among Ethnic and Minority Juvenile Populations."

Application kits are available from university grant offices and the Grants Management Branch, National Institute on Drug Abuse, Room 10-25, 5600 Fishers Lane, Rockville, Maryland 20857; Telephone (301) 443-6710. The original and six copies of applications (original and 2 copies, if PHS 5161 is used) must be submitted to the Division of Research Grants, Westwood Building, 5333 Westbard Avenue, Bethesda, Maryland 20892.

CONSULTATION AND FURTHER INFORMATION
Potential applicants are encouraged to seek pre-application consultation. Further information and consultation may be obtained by contacting:

Catherine S. Bell, M.S.
Division of Clinical Research
National Institute on Drug Abuse
5600 Fishers Lane, Room 10A-20
Rockville, Maryland 20857
Telephone (301) 443-1514

Pamela Swain and Cathy Sanders
Office of Juvenile Justice and Delinquency Prevention
633 Indiana Avenue, N.W., Room 782
Washington, D.C. 20531
Telephone (202) 724-5929
GUIDELINES

Although a broad range of methodological approaches will be considered, the following items should be addressed on the grant application. In all applications, the relevant research literature should be reviewed and summarized. The research problems to be addressed should be clearly stated and, when possible, specific hypotheses should be delineated. The population to be studied, the means to access the population, and the sampling techniques and the implications of the selected techniques should be described. Data collection instruments should be identified and their applicability discussed; when possible copies should be enclosed as appendices. Data scoring and data analyses strategies and specific procedures should be detailed.

For purposes of this program announcement, ethnic and minority populations are defined as members of the following groups: 1) Asian Pacific Islanders; 2) Blacks; 3) Hispanics; and 4) American Indian/Alaskan Natives. Drug abuse includes a broad range of substances (e.g., alcohol, marijuana, inhalants, cocaine, heroin).

REVIEW PROCEDURES

Review procedures for applications to this program conform to peer review procedures applicable to all research grants programs sponsored by the Alcohol, Drug Abuse, and Mental Health Administration. Applications are reviewed for scientific merit by an initial scientific peer review group.

The National Advisory Council on Drug Abuse performs a second review which may be based on policy as well as scientific merit considerations. Each application will be reviewed by a minimum of five persons. OJJDP and NIDA will nominate ad hoc committee minority members to review applications received under this announcement. After the Council provides final recommendations, applicants are notified of the results of the review. Only applications recommended for approval by the Council can be considered for funding.

REVIEW CRITERIA

The OJJDP will join NIDA in the scientific review of these proposals. The criteria for review of applications include overall quality and scientific merit of the proposed research. Scientific merit involves considerations such as originality, feasibility, soundness of the theoretical base in relation to previous research, soundness of approach and research design and data analysis plan, as well as the qualifications and experience of the investigators. The availability of suitable facilities to perform the proposed studies, the supportive nature of the research environment, and the appropriateness of the proposed budget are also important evaluative factors. Adequate provisions must be made for the protection of human subjects.

AWARD CRITERIA

Applications will be selected for funding primarily based on scientific and technical merit as determined by the peer review process and potential scientific contribution consistent with the priorities of this research announcement. Other factors may be considered including program priorities, the availability of funds, and the desirability of supporting minority investigators and/or minority institutions.

The final award decisions will be made jointly by NIDA and OJJDP.

RECEIPT AND REVIEW SCHEDULE

Applications will be reviewed according to the regular review schedule which is:

<table>
<thead>
<tr>
<th>Receipt of Applications</th>
<th>Initial Review</th>
<th>Advisory Council</th>
<th>Earliest Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 1</td>
<td>Oct/Nov</td>
<td>Jan/Feb</td>
<td>April 1</td>
</tr>
<tr>
<td>Oct 1</td>
<td>Feb/Mar</td>
<td>May/June</td>
<td>July 1</td>
</tr>
<tr>
<td>Feb 1</td>
<td>May/June</td>
<td>Sept/Oct</td>
<td>Dec 1</td>
</tr>
</tbody>
</table>

AVAILABILITY OF FUNDS/PERIOD OF SUPPORT

An estimated $500,000 will be available to initiate research projects in response to this announcement during fiscal year 1987. It is anticipated that three to five projects will be funded under this program announcement.
Funding for new applications or competing continuation applications in subsequent years will be dependent upon available funds and program priorities.

Applications submitted under this announcement may request support for a period of not less than one year and not more than 18 months.

Support for subsequent applications or competing continuations will be through grants for individual research projects. Such support may be requested for up to 5 years under (R01) investigator initiated grants program.

TERMS AND CONDITIONS

Grant funds may be used for expenses clearly related and necessary to carry out research projects, and must be expended in accordance with the PHS Grants Policy Statement. In general, grant funds may be used for direct costs which can be specifically identified with the project, including salaries, consultant fees, supplies, and equipment, and the allocable portion of allowable indirect costs of the institution. Research grant support is not provided to establish, add a component to, or operate prevention intervention services or programs. Support for research-related costs of intervention services and programs may be requested only for those particular costs and for that period of time required by the research. Such costs must be justified in terms of research objectives, methods, and design which promise to yield important knowledge and/or make a significant contribution to theoretical concepts. If such costs are requested, applicants must provide a description of other sources of support that have been explored. Because of limited research funds, there is a need to keep these types of costs to a minimum in research projects and, even where justified, the full amount requested may not be awarded. When support for program implementation is requested, the scope of the program should be limited to small groups or to clinical methods.

CIVIL RIGHTS COMPLIANCE

A All recipients of OJJDP assistance must comply with the non-discrimination requirements of the Juvenile Justice and Delinquency Prevention Act of 1974 as amended; Title VI of the Civil Rights Act of 1964; Section 504 of the Rehabilitation Act of 1973 as amended; Title IX of the Education Amendments of 1972; the Age Discrimination Act of 1975; and the Department of Justice Non-Discrimination Regulations (28 CFR Part 42, Subparts C, D, E, and G).

B In the event that a Federal or State court or Federal or State administrative agency makes a finding of discrimination after a due process hearing on the grounds of race, color, religion, national origin or sex against a recipient of funds, the recipient will forward a copy of the finding to the Office of Civil Rights Compliance (CRC) of the Office of Justice Programs.

C Applicants shall maintain such records and submit to the OJJDP upon request timely, complete and accurate data establishing the fact that no person or persons will be or have been denied or prohibited from obtaining employment in connection with any program activity funded in whole or in part with funds made available under this program because of their race, national origin, sex, religion, handicap or age. In the case of any program under which a primary recipient of Federal funds extends financial assistance to any other recipient, or contracts with any other person(s) or group(s), such other recipient, person(s) or group(s) shall also submit such compliance reports to the primary recipient as may be necessary to enable the primary recipient to assure its civil rights compliance obligations under any grant award.

Catalog of Federal Domestic Assistance No 13.279

DRUG ABUSE SERVICES RESEARCH CONFERENCE GRANTS - DA - 86 - 06

P.T. 42; K.W. 0404009

NATIONAL INSTITUTE ON DRUG ABUSE

Application Receipt Dates: June 1, October 1, February 1

The Division of Prevention and Communications of the National Institute on Drug Abuse seeks applications for conference grants. The purpose of the program is to stimulate discussion of research issues and to promote the dissemination of research findings in the areas of drug abuse prevention and treatment services. Grants will only be awarded for conferences which have a major focus on services research findings.
BACKGROUND

The National Institute on Drug Abuse (NIDA) wishes to support domestic and international conferences for the purpose of coordinating, exchanging, and disseminating ideas and information derived from or pertaining to drug abuse services research. For the purpose of this grant announcement "services research" is defined as research that has implications or significance for the delivery of prevention and treatment services and/or for the planning of those services. Conferences may be of limited scope focusing on a single area within services research, or global in scope drawing together different areas or approaches related to drug abuse services research issues. These conferences may be for the purposes of: sharing and disseminating information about drug abuse services research issues; providing a forum for the discussion of various prevention and treatment approaches and the implications of services research findings; and developing recommendations for future services research directions.

AREAS OF INTEREST

In view of the diversity of interests in the services provided within the field of drug abuse and the potential within services research, NIDA will not set rigid requirements about the types of services research conferences to be supported. Examples of appropriate drug abuse services research conference topics are: reviews of recent research findings in the areas of etiology/epidemiology and a consideration of their implications for prevention programming; reviews of studies and practices in the area of methadone treatment with suggestions for future study and for research-based practice, etc.

DEFINITIONS

The following definitions apply to this grant program:

1. Conference - a symposium, seminar, workshop, or any other organized and formal meeting lasting one or more days where persons assemble to exchange information and views or explore or clarify a defined subject, problem or area of knowledge, whether or not a published report results from such meeting.

2. International Conference - a meeting so designated by its sponsor, or one to which open invitations are issued on an equal basis to potential participants in two or more countries (not counting the U.S. or Canada). The meeting may be held in any country, including the United States.

3. Domestic Conference - a meeting held in the U.S. or Canada primarily for U.S. or U.S.-Canadian participation, but does not exclude those with invited foreign speakers.

4. Eligible Grantee - a U.S. institution eligible to receive grants from PHS Agencies, including scientific or professional societies. In the case of an international conference, the U.S. representative organization of an established international scientific or professional society is the eligible grantee. In exceptional cases, when there is no U.S. representative organization, grants to support a specific aspect of an international conference may be awarded directly to a foreign institution or international organization provided that (a) grants to foreign institutions or international organizations are not prohibited under the governing legislation, and (b) approval of the PHS Agency Head or his designee is obtained in each case. An individual is not eligible to receive a grant in support of a conference.

TERMS AND CONDITIONS OF SUPPORT

Drug Abuse Services Research Conference grant support will be provided for a period up to one year (not renewable for subsequent periods) and up to $25,000 of direct costs only. Indirect costs will not be allowed except in the most unusual circumstances and then only after negotiations in advance of the award between the applicant organization and the National Institute on Drug Abuse.

Grant funds may be used only for those expenses clearly related to and necessary to carry out the Drug Abuse Services Research Conference and must be expended in conformance with the Public Health Service Grants Policy Statement.

The Drug Abuse Services Research Conference grant is neither intended nor expected to cover all of the costs of a conference. Applicants must document additional funding resources.

APPLICATION ASSIGNMENT

State and local government agencies should use form PHS-5161. All other applicants should use the Standard PHS-398 (revised 5/82) research grant application form.
An application kit including instructions may be obtained from most institutional business offices, offices of sponsored research for most universities, colleges, medical schools, other major research facilities or from: Director, Division of Prevention and Communications, NIDA, Parklawn Building, room 10A-53, 5600 Fishers Lane, Rockville, Maryland 20857 (telephone: 301 443-6780).

Applicants are encouraged to inquire in advance of application concerning possible interest on the part of the National Institute on Drug Abuse in supporting the conference. Such inquiries should be directed to the Director, Division of Prevention and Communications.

The original and six copies (two if PHS-5161 is used) of the application should be sent directly to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westbard Building
5333 Westbard Avenue
Bethesda, Maryland 20205

APPLICATION REQUIREMENTS

The application kit includes general instructions. When completing the application, the applicant should specifically include the following information within the appropriate format:

A Title should include the term "conference," "symposium," "workshop," or other similar designation to assist in the identification of the request;

B Location of the conference;

C Expected number of registrants and type of audience expected. The criteria to be used by the applicant to select conference participants must be based on intellectual excellence, involvement/interests in drug abuse prevention or treatment services, and non-discriminatory factors, so that women, minorities, handicapped, and those from appropriate geographical areas have an equal choice to participate;

D Inclusive dates of conference;

E Composition and role of the organizing or planning committee, including brief biographical sketches of individuals responsible for planning the conference;

F Details of all services covered by the registration fee;

G Physical facilities and equipment required for the conduct of the meeting;

H Plans for publicity and publication of the proceedings;

I Details of proposed per diem subsistence rates and plans for payments of transportation costs;

J Justification of the conference, including the services research issues to be addressed, summary of relevant services research findings which apply to issues to be addressed at the conference, problems conference intends to clarify and the services research developments conference may stimulate;

K Information about all related conferences held on this subject during the past 3 years (if known), and a description of how the conference will relate to these past relevant activities;

L Conference format and proposed agenda, including a list of the principal areas or topics to be addressed, names of key participants with their credentials, and the basis for selection of topics and participants.

REVIEW PROCEDURES AND CRITERIA

Review Procedures

Applications will be reviewed for scientific merit and relevance to program goals in accordance with the standard review procedures of the Public Health Service; that is, each application will be assessed for scientific merit by an appropriate Initial Review Group (IRG), convened by the National Institute on Drug Abuse and composed primarily of non-Government experts. A copy of the summary statement from the initial peer review process will be sent to the principal investigator as soon as
possible after the review group meeting. Final review is to be done by the National Advisory Council on Drug Abuse. Only applications recommended for approval by the Council can be considered for funding.

Review Criteria

Criteria for scientific/technical merit review of applications will include the following:

- potential significance of the conference for the field of drug abuse services research and the application of findings from such research;
- technical merit of the conference plan;
- clarity and justification of overall objectives, aims, and goals of the conference;
- manner in which the conference is planned and organized, presence of an administrative and organizational structure that will facilitate attainment of the proposed objective(s) of the conference;
- competence/qualifications of project staff, principal director and other key personnel;
- participation of appropriate speakers/presenters and participants;
- appropriateness of budget for proposed conference;
- adequacy of proposed facilities and resources;
- appropriateness of the budget, staffing plan, and time frame to complete the conference;
- significance of proposed conference products/publications.

AWARD CRITERIA

In the decision to fund applications, the following will be considered:

- Quality and overall merit of the proposed conference as determined during the review process
- Availability of funds
- Program balance and relevance to the areas of services research

RECEIPT AND REVIEW SCHEDULE

Applications will be reviewed according to the review schedule which is:

<table>
<thead>
<tr>
<th>Receipt of Applications</th>
<th>Initial Review</th>
<th>Advisory Council</th>
<th>Earliest Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 1</td>
<td>Oct/Nov</td>
<td>Jan/Feb</td>
<td>April 1</td>
</tr>
<tr>
<td>Oct 1</td>
<td>Feb/Mar</td>
<td>May/June</td>
<td>July 1</td>
</tr>
<tr>
<td>Feb 1</td>
<td>May/June</td>
<td>Sept/Oct</td>
<td>Dec 1</td>
</tr>
</tbody>
</table>

AVAILABILITY OF FUNDS

In FY1987 it is anticipated that a minimum of $100,000 will be available to support Drug Abuse Services Research Conference Grants.

TERMINAL PROGRESS REPORT

A report of the conference must be prepared and six copies submitted to the NIDA Division of Prevention and Communications within 90 days after the termination of the grant. The report should include: (1) the grant number; (2) the title, date and place of the conference; (3) the name of the person shown on the application as the conference director, principal investigator, or program director; (4) name(s) of the organization(s) that conducted the conference; (5) list of the individuals who participated as speakers or discussants in the formally planned sessions of the meeting and their institutional affiliations; (6) copies of papers/speeches presented at the conference; and (7) summary of conference proceedings. Copies of proceedings or publications resulting from the meeting, must also be submitted when available.

Catalog of Federal Domestic Assistance No 13.279